Hologic Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Hologic Inc in the first quarter 2026?
Hologic Inc achieved a return on average equity (ROE) of 11.01 % in its first quarter 2026, this is above HOLX's average return on equity of 7.6%.
Hologic Incs equity during the 12 months ending in the first quarter 2026 are valued at $4 billion

ROE decreased relative to the period ending , due to the decline in net income.

Within the Medical Laboratories industry 9 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 909 to 1440.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 27 2025) I. Quarter	(Sep 27 2025) IV. Quarter	(Jun 28 2025) III. Quarter	(Mar 29 2025) II. Quarter	(Dec 28 2024) I. Quarter
Y / Y Equity Change	9.88 %	-1.6 %	-2.19 %	-4.66 %	-
Y / Y Net Income Change	-10.9 %	4.82 %	0.21 %	-	-18.46 %
Net Income (TTM) in Millions	544	566	557	557	744
Return On Equity (TTM)	11.01 %	11.74 %	11.51 %	11.44 %	15.11 %
HOLX's Total Ranking	# 1440	# 909	# 781	# 404	# 156
Equity (TTM) in Millions	5,245	5,048	4,843	4,619	4,773
Seq. Equity Change	3.91 %	4.24 %	4.85 %	-3.24 %	-6.95 %
Seq. Net Income Change	-4.33 %	-3.95 %	-	-	12.54 %

Back to HOLX Management Effectiveness >> HOLX's 5 Years Annual ROE >> Compare HOLX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 10
Sector	# 148
Overall	# 1440

Return On Equity Statistics
High	Average	Low
63.48 %	7.6 %	-56.92 %
(Mar 27 2021)		(Jun 28 2014)

HOLX Annual Return On Equity	(Sep 27 2025) 2025	(Sep 28 2024) 2024	(Sep 30 2023) 2023	(Sep 24 2022) 2022	(Sep 25 2021) 2021
Total Equity in Millions	5,048	5,130	5,017	4,876	4,219
Y / Y Equity Change	-1.6 %	2.25 %	2.89 %	15.59 %	55.82 %
Net Income in Millions	566	790	456	1,302	1,870
Y / Y Net Income Change	-28.35 %	73.14 %	-64.98 %	-30.36 %	68.37 %
Return On Equity	11.21 %	15.39 %	9.09 %	26.7 %	44.32 %

Back to HOLX Management Effectiveness >> HOLX's 5 Years Annual ROE >> Compare HOLX ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 11.21 %, due to deterioration of net income.

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HOLX's' Return on Equity at Yahoo Finance
HOLX's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HOLX's Competitors
Subscribers only: Roe for Hologic Inc's Suppliers
Subscribers only: Return On Equity for HOLX's Customers

Companies with similar Return On Equity at Dec 27 2025, within Healthcare Sector	ROE
Pro dex Inc	30.23 %
Novartis Ag	30.00 %
Incyte Corporation	29.15 %
Waters Corporation	28.52 %
Puma Biotechnology Inc	27.81 %
Resmed Inc	25.18 %
Encompass Health Corporation	24.76 %
Prestige Consumer Healthcare Inc	24.66 %
Catalyst Pharmaceuticals Inc	24.32 %
Collegium Pharmaceutical Inc	24.11 %
Xoma Royalty Corporation	23.97 %
Chemed Corporation	23.92 %
Iradimed Corporation	23.83 %
Lifevantage Corp	23.04 %
Hims and Hers Health Inc	22.99 %
Vertex Pharmaceuticals Inc	22.70 %
Pacs Group Inc	22.54 %
Spero Therapeutics Inc	22.53 %
Iqvia Holdings Inc	22.05 %
Ge Healthcare Technologies Inc	21.90 %
Msa Safety Inc	21.82 %
Mimedx Group Inc	21.24 %
Universal Health Services Inc	21.19 %
Inspire Medical Systems inc	21.07 %
Astrazeneca Plc	21.00 %
Haemonetics Corporation	20.80 %
Sbc Medical Group Holdings Incorporated	20.79 %
Lantheus Holdings Inc	20.58 %
Electromed Inc	20.54 %
Teva Pharmaceutical Industries Limited	20.07 %

Date modified: 2026-09-26T06:54:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.